Bladder Cancer Treatment Enters Modern Era: Pembrolizumab and Enfortumab Vedotin Lead the Charge
A new treatment combination is significantly improving survival outcomes for patients with muscle-invasive bladder cancer, offering a potential paradigm shift in how this aggressive disease is managed. Data from the KEYNOTE-B15 study reveals that neoadjuvant and adjuvant pembrolizumab (Keytruda) plus enfortumab vedotin-ejfv demonstrate a substantial benefit over traditional cisplatin-based chemotherapy.
A Landmark Improvement in Survival
The KEYNOTE-B15 study, presented at the ASCO Genitourinary Cancers Symposium, showed patients receiving pembrolizumab and enfortumab vedotin experienced a 47% improvement in event-free survival (EFS) and a 35% improvement in overall survival (OS). This marks the first time in nearly 25 years a non-platinum-based regimen has surpassed cisplatin-based chemotherapy in improving survival, according to Matthew D. Galsky, MD, professor of medicine at Mount Sinai.
How the Regimen Works
The treatment protocol involves four cycles of enfortumab vedotin-ejfv (1.25 mg/kg twice every 3 weeks) and pembrolizumab (200 mg once every 3 weeks) before surgery. Following cystectomy, patients receive five additional cycles of enfortumab vedotin-ejfv and 13 cycles of pembrolizumab. This approach leverages the power of immunotherapy – pembrolizumab, which helps the immune system recognize and attack cancer cells – combined with an antibody-drug conjugate – enfortumab vedotin-ejfv, which delivers a cytotoxic agent directly to cancer cells.
Pathological Complete Response Rates Soar
Beyond survival benefits, the combination therapy also demonstrated a significantly higher pathologic complete response rate – meaning no cancer cells were found in the removed tissue after surgery – of 55.8% compared to 32.5% with cisplatin-based chemotherapy (P < .0001). This suggests a more effective eradication of the cancer before and after surgical intervention.
Safety Profile Considerations
While the treatment combination showed promising results, it’s significant to consider the safety profile. Patients receiving enfortumab vedotin-ejfv plus pembrolizumab experienced higher rates of pruritus, diarrhea, alopecia, and rash. However, rates of anemia, nausea, neutropenia, and thrombocytopenia were lower compared to those receiving cisplatin-based chemotherapy. The safety profiles of both arms were described as “consistent” with previous experience.
Expanding Treatment Options for Unfit Patients
These findings build upon previous research, including the KEYNOTE-905/EV-303 study, which demonstrated improved outcomes with the pembrolizumab and enfortumab vedotin combination versus cystectomy alone for patients ineligible for cisplatin. This regimen received FDA approval in November 2025, further solidifying its role in bladder cancer treatment.
Future Directions: Refining the Approach
Researchers are now exploring whether both neoadjuvant and adjuvant therapy are necessary for optimal outcomes. The integration of circulating tumor DNA (ctDNA) analysis may also play a crucial role in personalizing treatment strategies and identifying patients most likely to benefit from this combination therapy.
The Promise of Personalized Medicine in Bladder Cancer
The advancements highlighted by the KEYNOTE-B15 study and related research signal a move towards more personalized and effective treatment strategies for muscle-invasive bladder cancer. Combining immunotherapy with targeted therapies, alongside advanced diagnostic tools like ctDNA analysis, holds the potential to significantly improve outcomes and quality of life for patients facing this challenging disease.
Did you know?
Muscle-invasive bladder cancer affects approximately 70,000 people in the United States each year, and it’s often diagnosed at a late stage, making treatment more difficult.
FAQ
- What is pembrolizumab? Pembrolizumab (Keytruda) is an immunotherapy drug that helps your immune system fight cancer.
- What is enfortumab vedotin-ejfv? Enfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate that delivers a cytotoxic agent directly to cancer cells.
- Is this treatment right for everyone with bladder cancer? This treatment is currently indicated for patients with muscle-invasive bladder cancer. Your doctor will determine if it’s appropriate for your specific situation.
- What are the potential side effects? Potential side effects include pruritus, diarrhea, alopecia, rash, anemia, nausea, neutropenia, and thrombocytopenia.
Explore more articles on bladder cancer treatment and research here.
